BioXcel Therapeutics, Inc. (BTAI)

Nasdaq Pharmaceutical Pharmaceutical Preparations SIC: 2834
A
Pipeline Grade

Financial Position (from SEC Filings)

$17.2M
Cash & Equivalents
$11.8M
Quarterly Burn Rate
4 mo
Est. Cash Runway
$40M
Market Cap

Estimated from most recent SEC quarterly filing. View SEC filings

Drug Pipeline (1 Assets)

DrugPhaseIndications
DEXMEDETOMIDINE HYDROCHLORIDE
IGALMI 		APPROVED —

Upcoming Catalysts

No upcoming catalysts detected for this company.

More Analysis

AI Stock Score

SEC EDGAR fundamental analysis with Claude AI & ChatGPT ratings for BTAI.

SEC EDGAR Filings

All SEC filings for BioXcel Therapeutics, Inc. on EDGAR.

Full Calendar

View all upcoming FDA catalysts across all biotech companies.